DynPort Vaccine Company

DynPort Vaccine Company is an American biotechnology company based in Frederick, Maryland. It is “dedicated to the development and licensure of safe and efficacious biodefense vaccines.”

History

DynPort was founded in 1997 as a joint venture between defense contractor DynCorp and Porton International, a wholly-owned subsidiary of Ipsen.1) 2) That year, the United States Department of Defense (DoD), through its Joint Vaccine Acquisition Program (JVAP), contracted DynPort to manufacture 300,000 doses of a new smallpox vaccine for the military.3) The company began working on the project in 1998.

Dr. Robert Malone joined the company as Associate Director of Clinical Research in 2002, leaving the position in 2003.4)

Puppet Masters of the Pandemic. Part 1: What Did The CIA Do in Wuhan?“ Part 1 of an interview with the New American Magazine - Robert Malone Aug 3, 2023

We know that with the biodefense enterprise, broadly writ, in the United States, the CIA is intimately integrated into all levels. That's why I have all these CIA contacts is that I was brought into the biodefense community after 9/11 when I went to work for DynPort Vaccine company (because the Norwegian investors in the newco which Jill and I helped launch had pulled out after 9-11 and we had no income). 5)

On March 30, 2004, Commonwealth Biotechnologies announced it had entered a partnership with DynPort through which the companies would “co-venture wherever appropriate to compete for new biodefense vaccine development funding.”6)

Activities

Covid-19 Pandemic Cures

A Killer Enterprise: How One of Big Pharma’s Most Corrupt Companies Plans to Corner the Covid-19 Cure Market

BY WHITNEY WEBB APRIL 9, 2020 Originally published at The Last American Vagabond

“One of the most politically-connected yet scandal ridden vaccine companies in the United States, with troubling ties to the 2001 anthrax attacks and opioid crisis, is set to profit handsomely from the current Coronavirus crisis.“

In August 2001, biopharmaceutical company BioPort faced imminent disaster. A series of company scandals, controversial federal bail-outs and severe, adverse health reactions among U.S. troops were causing both Congress and the Pentagon to reconsider its multi-million dollar contract to provide the military with an anthrax vaccine.

Formed for the sole purpose of acquiring a publicly-owned company in Michigan that held the exclusive license to manufacture the only FDA-approved anthrax vaccine in the United States, BioPort sought to quickly expand the size and scope of its contracts with the U.S. military. This strategy was made possible thanks to the former head of the Joints Chiefs of Staff, Adm. William Crowe, who would prove highly instrumental in the rise of BioPort’s vaccine monopoly and its subsequent, aggressive hiring of former government officials as lobbyists.

Yet, soon after scoring these multi-million dollar contracts and securing a monopoly on anthrax vaccines, BioPort would claim that they were flailing financially and would subsequently be bailed out to the tune of $24 million at the Pentagon’s request, which cited “national security concerns” as justification.

BioPort would be then renamed and repackaged as Emergent Biosolutions in 2004. 7)

Products

DynPort developed vaccines and related biologicals for a number of diseases including:8)

Organization

Personnel

Name Position Notes
Terry Irgens President (former) Logicon, Defense Personnel Support Center, Naval Medical Logistics Command (NMLC)
Michael Langford Sr. Vice President & Chief Scientific Officer (former)9) United States Army, United States Army Acquisition Corps
Robert Malone Associate Director of Clinical Research (former) Worked on DynPort's smallpox vaccine
1)
Hogan, B. (January/February 2002). A Biodefense Boondoggle. Mother Jones. https://web.archive.org/web/20051129154849/http://www.motherjones.com//news/outfront/2002/01/biodefense.html
2) , 6)
Harris, R. B. (2004, March 30). Commonwealth Biotechnologies, Inc. Launches New Biodefense Business Initiative. Securities and Exchange Commission. http://archive.today/2023.03.20-195208/https://www.sec.gov/Archives/edgar/data/1042418/000119312504053263/dex991.htm
3)
Cohen, J., & Marshall, E. (2001, October 19). Vaccines for Defense: A System in Distress. UCLA Department of Epidemiology. http://archive.today/2021.12.13-221406/http://www.ph.ucla.edu/epi/bioter/vaccinesfordefense.html
9)
Leadership. DynPort. Retrieved December 8, 2002, from https://web.archive.org/web/20021208085639/http://www.dynport.com/leadership.htm
Back to top